Welgene Biotech Co.,Ltd. (TPEX:6661)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.50
-0.15 (-0.80%)
Apr 20, 2026, 10:25 AM CST
Market Cap434.62M -20.6%
Revenue (ttm)375.94M +16.6%
Net Income1.33M +20.1%
EPS0.06 +26.3%
Shares Out23.30M
PE Ratio326.79
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,000
Average Volume7,228
Open18.05
Previous Close18.65
Day's Range18.00 - 18.50
52-Week Range17.60 - 24.05
Beta0.29
RSI50.35
Earnings DateMay 8, 2026

About Welgene Biotech

Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables, and instruments, as well as software services. Welgene Biotech Co.,Ltd. was founded in 2003 and is based in Taipei City, Taiwan. [Read more]

Sector Healthcare
Founded 2003
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6661
Full Company Profile

Financial Performance

In 2025, Welgene Biotech's revenue was 375.94 million, an increase of 16.55% compared to the previous year's 322.55 million. Earnings were 1.33 million, an increase of 20.14%.

Financial Statements